FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling […]
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease Read More »
Gene Therapy Notes